Blog
RSS FeedPosted by Michael Wonder on 16 May 2022
PHARMAC widens access to medicine for RSV
16 May 2022 - PHARMAC has announced today that it will be funding the preventative treatment, palivizumab, for the next two ...
Posted by Michael Wonder on 15 May 2022
PHARMAC publishes agenda for May 2022 PTAC meeting
12 May 2022 - Yet another PTAC meeting with very few applications for new medicines/medicines still under patent protection. ...
Posted by Michael Wonder on 10 May 2022
Calls for Health Minister to release final report from PHARMAC review
11 May 2022 - Health Minister Andrew Little is facing calls to release the final report from a review of ...
Posted by Michael Wonder on 04 May 2022
People with multiple sclerosis unable to access 'life-changing' treatment in NZ
5 May 2022 - New Zealanders with multiple sclerosis say their only hope of slowing the disease is not available ...
Posted by Michael Wonder on 02 May 2022
Mum and son hold their breath for cystic fibrosis drug Trikafta ahead of Budget
29 April 2022 - Hamish Mountfort is a smart, well-spoken and confident 22-year-old who’s dying, literally, to dedicate his life ...
Posted by Michael Wonder on 01 May 2022
New Zealand Pharmaceutical Schedule - 1 May 2022
1 May 2022 - The May 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 28 Apr 2022
Cancer agency report duplicates PHARMAC role
28 April 2022 - The Cancer Control Agency’s analysis of the gap between Australia and New Zealand in funding 18 selected ...
Posted by Michael Wonder on 28 Apr 2022
Access criteria for antiviral treatments widened as molnupiravir arrives in New Zealand
28 April 2022 - PHARMAC is widening access to the antivirals to treat people with early COVID-19, after receiving feedback from ...
Posted by Michael Wonder on 27 Apr 2022
PHARMAC welcomes analysis into cancer medicines in Aotearoa
28 April 2022 - PHARMAC welcomes a new report released today by Te Aho o Te Kahu (the Cancer Control ...
Posted by Michael Wonder on 27 Apr 2022
Arthritis patients suffer after medication diverted due to COVID-19
27 April 2022 - Rheumatoid arthritis sufferers have been left in pain as one of their medications was diverted for ...
Posted by Michael Wonder on 11 Apr 2022
8,700 more Pacific peoples need treatment to prevent gout each year to achieve equity
11 April 2022 - PHARMAC has released the Pacific peoples health – Gout data insights report today. ...
Posted by Michael Wonder on 01 Apr 2022
Funding Trikafta for Kiwis with cystic fibrosis - setting the record straight
31 March 2022 - On Monday 28 March, Carmen Shanks presented her Parliamentary Petition to MP Shanan Halbert, urging the ...
Posted by Michael Wonder on 31 Mar 2022
New Zealand Pharmaceutical Schedule -1 April 2022
1 April 2022 - The April 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Mar 2022
Statement from Rare Disorders NZ re Minister Little's comments on PHARMAC funding
31 March 2022 - Rare Disorders NZ is extremely frustrated to hear the Minister of Health this week dismiss the call ...
Posted by Michael Wonder on 31 Mar 2022
PHARMAC secures advance purchase agreement for a pre-exposure COVID-19 treatment
31 March 2022 - PHARMAC has negotiated an agreement with AstraZeneca for its pre-exposure prophylactic COVID-19 treatment, which would be targeted ...